Abstract
Double-blind randomized placebo-controlled trials, in which a new approval-seeking drug is compared to placebo, are generally considered to be the gold standard for evaluating the efficacy of a psychopharmacological intervention in the treatment of affective disorders. However, this type of study has substantial limitations regarding the external validity of its results. Therefore, alternatives within randomized controlled trials, such as non-inferiority trials or study designs in which the new drug or placebo is given simultaneously on top of standard antidepressant or anti-manic treatment are of substantial interest. In addition, innovative statistical approaches such as marginal structural models or Q-learning should be employed to evaluate potential causal effects associated with different fixed treatment regimes that are realized in actual clinical practice and help to establish treatment recommendations that are tailored to individual patient characteristics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.